Replies to post #180629 on Biotech Values

[DewDiligence]

Re: ENTA valuation model

have you made any changes to the assumptions or the ultimate number in your valuation model?

Not since the latest update in Dec 2015, when GILD announced pricing for standalone Sovaldi.

My pricing assumptions for the Sovaldi + Ledipasvir combination and for ABBV/ENTA’s 3-DAA regimen, which are discussed in #msg-100491031, are consistent with the valuation model in #msg-94993406.

When GILD finally announces the pricing of Sovaldi + Ledipasvir (upon FDA approval), I’ll update the model if necessary.